NEBULIZATION WITH HARIDRA ARKA VERSUS METERED DOSE INHALER IN ACUTE EXACERBATION OF BRONCHIAL ASTHMA: AN OPEN LABEL, NON-RANDOMIZED, NON-INFERIORITY TRIAL

Objective: Present study was undertaken to compare the efficacy of Metered dose inhaler (MDI) with spacer and with Dry powder inhaler (DPI) for delivery of salbutamol in acute exacerbation of bronchial asthma. It is a randomized controlled trial study. Material and Methods: A total of 78 children in the age group of 6-14 years who presented with a mild or moderate acute exacerbation of asthma were included in the study. Salbutamol dose of 400µg were given to all the children’s by either a MDI with spacer or a DPI in randomized pattern. All the changes in the wheezing and accessory muscle scores, Sa02, and PEFR were noted. Results: Out of 78 children, 42 were assigned to the MDI spacer group and 36 to rotahaler (DPI) group. After receiving treatment, the PEFR improved by about 14% in both the groups. The oxygen saturation increased by 2.1% in both the groups. Within each group, the improvement in PEFR, Sa02, wheeze and accessory muscle score after the treatment was statistically significant. Conclusion: Metered dose inhaler with spacer and Dry powder inhaler are equally effective in delivering salbutamol in therapy of mild to moderate acute exacerbations of bronchial asthma in children between 6-14 years of age Keyword: DPI, Salbutamol, Treatment, Asthma, Children, MDI, PEFR

Download Full-text

A COMPARATIVE STUDY OF METERED DOSE INHALER WITH SPACER AND DRY POWDER INHALER FOR DELIVERY OF SALBUTAMOL IN ACUTE EXACERBATIONS OF BRONCHIAL ASTHMA

10.36106/paripex/7403374 ◽

2021 ◽

pp. 25-26

Author(s):

Rakesh Kumar

Keyword(s):

Acute Exacerbation ◽

Bronchial Asthma ◽

Statistical Tests ◽

Dry Powder Inhaler ◽

Dose Inhaler ◽

Metered Dose Inhaler ◽

Dry Powder ◽

Accessory Muscle ◽

Acute Exacerbations ◽

Metered Dose

Objective: To compare the efficacy of metered dose inhaler with spacer with dry powder inhaler for delivery of salbutamol in acute exacerbation of bronchial asthma Design:Randomized controlled trial in the Setting of Department of Pediatrics, Patna Medical College and Hospital Patna Methods: Children in the age group of 5 - 12 years who presented with a mild or moderate acute exacerbation of asthma were randomized to receive 400 mcg salbutamol by either a MDI with spacer or a DPI. The changes in the wheezing and accessory muscle scores, SaO2, and PEFR were recorded and subjected to statistical tests for significance. Results: Two hundred and fifty-three children were studied; 128 were assigned to the MDI-spacer group and 125 to rotahaler (DPI) group. After receiving treatment, the PEFR improved by about 11% in both the groups. The oxygen saturation increased by 2% in both the groups.Within each group, the improvement in PETR, SaO2, wheeze and accessory muscle score after the treatment was statistically significant. Conclusion: Metered dose inhaler with spacer and dry powder inhaler are equally effective in delivering salbutamol in therapy of mild to moderate acute exacerbations of bronchial asthma in children between 5-12 years of age.

Download Full-text

Metered-Dose Inhaler with Spacer versus Nebuliser for Acute Exacerbation of Asthma-A Literature Review

The Australian Journal of Hospital Pharmacy ◽

10.1002/jppr2001313189 ◽

2001 ◽

Vol 31 (3) ◽

pp. 189-192

Author(s):

Hesham S Al-Sallami ◽

Patrick A Ball ◽

Andrew K Davey

Keyword(s):

Literature Review ◽

Acute Exacerbation ◽

Dose Inhaler ◽

Metered Dose Inhaler ◽

Metered Dose

Download Full-text

Similar Results in Children with Asthma for Steady State Pharmacokinetic Parameters of Ciclesonide Inhaled with or without Spacer

Clinical Medicine Insights Pediatrics ◽

10.4137/cmped.s4311 ◽

2010 ◽

Vol 4 ◽

pp. CMPed.S4311 ◽

Cited By ~ 4

Author(s):

H. Boss ◽

P. Minic ◽

R. Nave

Keyword(s):

Active Metabolite ◽

Day Treatment ◽

Systemic Exposure ◽

Dose Inhaler ◽

Pharmacokinetic Parameters ◽

Metered Dose Inhaler ◽

Inhaled Corticosteroid ◽

Open Label ◽

Metered Dose ◽

Children With Asthma

Background Ciclesonide is an inhaled corticosteroid administered by a metered dose inhaler (MDI) to treat bronchial asthma. After inhalation, the inactive ciclesonide is converted by esterases in the airways to active metabolite desisobutyryl-ciclesonide (des-CIC). Aim To compare the pharmacokinetic (PK) parameters of des-CIC in children after administration of therapeutic dose of ciclesonide with and without spacer (AeroChamber Plus™). Methods Open-label, 3 period, cross over, repeated dose, PK study in 37 children with mild to moderate stable asthma (age: 6–11 y; body weight: 20–53 kg). During each 7-day treatment period, ciclesonide was inhaled once in the morning: A) 160 μg MDI with spacer, B) 80 μg MDI with spacer, and C) 160 μg MDI without spacer. Serum PK parameters of ciclesonide and des-CIC were determined on Day 7 of each period. The primary PK parameters were the AUCτ and Cmax for des-CIC. Results Inhaling ciclesonide with spacer led to a dose proportional systemic exposure (AUCτ) of des-CIC (0.316 μg*h/L for 80 μg and 0.663 μg*h/L for 160 μg). The dose-normalized systemic exposure for des-CIC (based on AUCτ) was 27% higher after inhalation of ciclesonide 80 μg or 160 μg with spacer than without spacer; the corresponding Cmax values for des-CIC were, respectively, 63% and 55% higher with spacer. No clinically relevant abnormalities or adverse drug reactions were observed. Conclusions Inhalation of therapeutic ciclesonide dose with spacer led to a slight increase in the systemic exposure of des-CIC, which does not warrant dose adjustment.

Download Full-text